Article Text

Download PDFPDF
Recent progress in conventional and biologic therapy for systemic lupus erythematosus
  1. David Wofsy
  1. Correspondence to Dr David Wofsy, Division of Rheumatology, The Rosalind Russell Medical Research Center for Arthritis at the University of California San Francisco, San Francisco, CA, 94143, USA; wofsyd{at}


The recent approval of belimumab for the treatment of systemic lupus erythematosus (SLE) ended a decade in which there was mounting optimism about the prospect for developing biologically based therapies for SLE. During this same period, steady progress had been made in understanding and applying conventional therapies for SLE. These advances in the use of conventional therapies provide an important frame of reference for evaluating the novel biologic therapies that are expected to emerge in the near future.

  • Systemic Lupus Erythematosus
  • Lupus Nephritis
  • Cyclophosphamide

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.